Nectar Lifesciences will hold a board meeting on May 30, 2026, to review and approve the final financial results for FY2025-26, in line with SEBI regulations, and discuss any related business matters.

Nectar Lifesciences has pushed back the deadline for its capsule business transfer to July 31, 2026, as stated in a new slump sale agreement, maintaining the initial terms announced earlier.

Nectar Lifesciences has successfully resolved a tax dispute from the 2017-18 fiscal year, with no financial impact on the company. The objections raised against them for the years 2018-22 have been dismissed, and they are now permitted to file new petitions. This development indicates that Nectar Lifesciences will not face any financial liability from these disputes.